Activation-induced cytidine deaminase links bile duct inflammation to human cholangiocarcinoma

Hepatology

Volumn 47, Issue 3, 2008, Pages 888-896

  Komori, Junji ^a   Marusawa, Hiroyuki ^a   Machimoto, Takafumi ^a   Endo, Yoko ^a   Kinoshita, Kazuo ^b   Kou, Tadayuki ^a   Haga, Hironori ^a   Ikai, Iwao ^a   Uemoto, Shinji ^a   Chiba, Tsutomu ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Shiga Medical Center   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATION INDUCED CYTIDINE DEAMINASE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DNA; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN P53; RNA; TUMOR NECROSIS FACTOR ALPHA; AICDA (ACTIVATION INDUCED CYTIDINE DEAMINASE); AICDA (ACTIVATION-INDUCED CYTIDINE DEAMINASE); CYTIDINE DEAMINASE; CYTOKINE; MYC PROTEIN; MYC PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ARTICLE; BILE DUCT; BILE DUCT CARCINOMA; CANCER CELL; CARCINOGENESIS; CHOLANGITIS; CHRONIC INFLAMMATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; GENE SEQUENCE; GENETIC SUSCEPTIBILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER; LIVER CELL; MALE; MUTAGENESIS; MUTAGENICITY; ONCOGENE C MYC; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FAMILY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EDITING; SOMATIC MUTATION; STATISTICAL SIGNIFICANCE; TUMOR SUPPRESSOR GENE; AGED; BILE DUCT TUMOR; CELL CULTURE; DRUG EFFECT; ENZYMOLOGY; GENETIC PREDISPOSITION; GENETICS; INTRAHEPATIC BILE DUCT; METABOLISM; MIDDLE AGED; MUTATION; PATHOLOGY;

AGED; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CELLS, CULTURED; CHOLANGIOCARCINOMA; CHOLANGITIS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYTIDINE DEAMINASE; CYTOKINES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; MUTAGENESIS; MUTATION; PROTO-ONCOGENE PROTEINS C-MYC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 40949132893     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.22125     Document Type: Article

References (33)

1. Patel T. Cholangiocarcinoma. Nat Clin Pract Gastroenterol Hepatol 2006;3:33-42.
2. Gores GJ. Cholangiocarcinoma: current concepts and insights. HEPATOLOGY 2003;37:961-969.
3. Honjo T, Kinoshita K, Muramatsu M. Molecular mechanism of class switch recombination: linkage with somatic hypermutation. Annu Rev Immunol 2002;20:165-196.
4. Honjo T, Muramatsu M, Fagarasan S. AID: how does it aid antibody diversity? Immunity 2004;20:659-668.
5. Okazaki IM, Hiai H, Kakazu N, Yamada S, Muramatsu M, Kinoshita K, et al. Constitutive expression of AID leads to tumorigenesis. J Exp Med 2003;197:1173-1181.
6. Endo Y, Marusawa H, Kinoshita K, Morisawa T, Sakurai T, Okazaki IM, et al. Expression of activation-induced cytidine deaminase in human hepatocytes via NF-κB signaling. Oncogene 2007;26:5587-5595.
7. Kou T, Marusawa H, Kinoshita K, Endo Y, Okazaki IM, Ueda Y, et al. Expression of activation-induced cytidine deaminase in human hepatocytes during hepatocarcinogenesis. Int J Cancer 2007;120:469-476.
8. Matsumoto Y, Marusawa H, Kinoshita K, Endo Y, Kou T, Morisawa T, et al. Helicobacter pylori infection triggers aberrant expression of activation-induced cytidine deaminase in gastric epithelium. Nat Med 2007;13:470-476.
9. Sell S, Dunsford HA. Evidence for the stem cell origin of hepatocellular carcinoma and cholangiocarcinoma. Am J Pathol 1989;134:1347-1363.
10. Sirica AE. Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy. HEPATOLOGY 2005;41:5-15.
11. Theise ND, Yao JL, Harada K, Hytiroglou P, Portmann B, Thung SN, et al. Hepatic 'stem cell' malignancies in adults: four cases. Histopathology 2003;43:263-271.
12. Marusawa H, Uemoto S, Hijikata M, Ueda Y, Tanaka K, Shimotohno K, et al. Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen. HEPATOLOGY 2000;31:488-495.
13. Marusawa H, Hijikata M, Watashi K, Chiba T, Shimotohno K. Regulation of Fas-mediated apoptosis by NF-κB activity in human hepatocyte derived cell lines. Microbiol Immunol 2001;45:483-489.
14. Fagarasan S, Kinoshita K, Muramatsu M, Ikuta K, Honjo T. In situ class switching and differentiation to IgA-producing cells in the gut lamina propria. Nature 2001;413:639-643.
15. Marusawa H, Hijikata M, Chiba T, Shimotohno K. Hepatitis C virus core protein inhibits Fas- and tumor necrosis factor α-mediated apoptosis via NF-κB activation. J Virol 1999;73:4713-4720.
16. Toda Y, Kono K, Abiru H, Kokuryo K, Endo M, Yaegashi H, et al. Application of tyramide signal amplification system to immunohistochemistry: a potent method to localize antigens that are not detectable by ordinary method. Pathol Int 1999;49:479-483.
17. Aoki CA, Bowlus CL, Gershwin ME. The immunobiology of primary sclerosing cholangitis. Autoimmun Rev 2005;4:137-143.
18. Bo X, Broome U, Remberger M, Sumitran-Holgersson S. Tumour necrosis factor α impairs function of liver derived T lymphocytes and natural killer cells in patients with primary sclerosing cholangitis. Gut 2001;49:131-141.
19. Angulo P, Lindor KD. Primary sclerosing cholangitis. HEPATOLOGY 1999; 30:325-332.
20. Khan SA, Thomas HC, Toledano MB, Cox IJ, Taylor-Robinson SD. p53 Mutations in human cholangiocarcinoma: a review. Liver Int 2005;25: 704-716.
21. INK4a promoter mutations are frequent in primary sclerosing cholangitis (PSC) and PSC-associated cholangiocarcinoma. Gastroenterology 2002;123:1090-1098.
22. Berthiaume EP, Wands J. The molecular pathogenesis of cholangiocarcinoma. Semin Liver Dis 2004;24:127-137.
23. Muramatsu M, Sankaranand VS, Anant S, Sugai M, Kinoshita K, Davidson NO, et al. Specific expression of activation-induced cytidine deaminase (AID), a novel member of the RNA-editing deaminase family in germinal center B cells. J Biol Chem 1999;274:18470-18476.
24. Kinoshita K, Nonaka T. The dark side of activation-induced cytidine deaminase: relationship with leukemia and beyond. Int J Hematol 2006; 83:201-207.
25. Yamanaka S, Balestra ME, Ferrell LD, Fan J, Arnold KS, Taylor S, et al. Apolipoprotein B mRNA-editing protein induces hepatocellular carcinoma and dysplasia in transgenic animals. Proc Natl Acad Sci U S A 1995;92:8483-8487.
26. Lee YM, Kaplan MM. Primary sclerosing cholangitis. N Engl J Med 1995; 332:924-933.
27. MacDonald TT, Hutchings P, Choy MY, Murch S, Cooke A. Tumour necrosis factor-α and interferon-γ production measured at the single cell level in normal and inflamed human intestine. Clin Exp Immunol 1990; 81:301-305.
28. Powrie F. T cells in inflammatory bowel disease: protective and pathogenic roles. Immunity 1995;3:171-174.
29. Karin M, Greten FR. NF-κB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005;5:749-759.
30. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, et al. NF-κB functions as a tumour promoter in inflammation-associated cancer. Nature 2004;431:461-466.
31. Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ, et al. IKKβ links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004;118:285-296.
32. Rizzi PM, Ryder SD, Portmann B, Ramage JK, Naoumov NV, Williams R. p53 Protein overexpression in cholangiocarcinoma arising in primary sclerosing cholangitis. Gut 1996;38:265-268.
33. Boberg KM, Schrumpf E, Bergquist A, Broome U, Pares A, Remotti H, et al. Cholangiocarcinoma in primary sclerosing cholangitis: K-ras mutations and Tp53 dysfunction are implicated in the neoplastic development. J Hepatol 2000;32:374-380.